-
02
2026
2026.02.23 -
Caliway Completes Australian HREC Submission for CBL-0206, Advancing Asia-Pacific Clinical Strategy
CBL-0206 Phase 2 study of Caliway’s first-in-class large-area localized fat reduction drug, CBL-514, has completed Australian HREC submission. The study will be conducted in Taiwan and Australia, with an estimated enrollment of approximately 250 participants. The study aims to expand safety and efficacy data in Asian populations, supporting future NDA filings and Caliway’s global and regional dual-track licensing strategy
